A FAST-GROWING EUROPEAN BIOTECH COMPANY

Born from the heart of Academia

CELLMABS STORY

CellmAbs is a spin-off company from NOVA University of Lisbon and was incorporated in 2019 with the investment of two of the largest Life Science Venture Capital firms in Portugal.

CellmAbs is a fast-growing biotech company with an international, experienced team that has generated several preclinical candidates targeting solid tumors based on a world-leading understanding of cancer-specific glycan targets.

Therapeutic modalities include:

  • Antibody-Drug Conjugates

  • Bispecific T-Cell Engagers

  • Cell Therapies

A SUCCESSFUL CASE OF TRANSLATIONAL RESEARCH

Innovation developed between NOVA University and the Portuguese Institute of Oncology Porto

  • Faculty of Sciences and Technology

  • NOVA Medical School

  • Portuguese Institute of Oncology

INVESTORS

AAC 15/SI/2020

SISTEMA DE INCENTIVOS
ATIVIDADES DE INVESTIGAÇÃO E DESENVOLVIMENTO E INVESTIMENTO EM INFRAESTRUTURAS DE ENSAIO E OTIMIZAÇÃO (UPSCALING) NO CONTEXTO DO COVID-19

I&D Empresas - COVID-19